Sugammadex Reduces Antiemetic Effect of Dexamethasone

Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

PONV Nausea Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Nausea and Vomiting Signs and Symptoms Signs and Symptoms, Digestive Vomiting

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The study will use de-identified retrospective data to conduct a cross-sectional study to determine the effect of sugammadex on the antiemetic efficacy of dexamethasone in elective adult surgical patients who underwent surgery in a tertiary care center between January 1 2023 and January 1 2024 . The investigators will conduct univariate and multivariate analysis to assess the effect.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Older than 18 years old
Elective surgery
ASA 1, 2, 3
At least one risk factor for PONV

Exclusion criteria

Pregnancy
Receiving antiemetics prior to arrival to preoperative holding area
Receiving opioids prior to arrival to preoperative holding area
Admission to ICU
Altered mental status
Rapid sequence induction
Nausea or vomiting before surgery

Treatment and study plan

Primary outcomes

Rate of PONV

Time frame: 2 hours after admission to PACU

Number of events of PONV during 2 hours after admission to PACU

Study contacts

Contact information is provided by the study sponsor or research team.

Efrain Riveros Perez, MD

CONTACT

[email protected]

7067217361

Sponsors and collaborators

Lead sponsor

Augusta University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Mar 30, 2025
Registry last updated: Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting